Drug Trial Radar · NCT02658890
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Last checked: Nov 19, 2026Latest source record: Aug 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
627
Actual
Start
Apr 14, 2016
Primary completion
Oct 26, 2021
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
Conditions
- Advanced Cancer
- Melanoma
- Non-Small Cell Lung Cancer
Interventions
BMS-986205Drug
NivolumabDrug
IpilimumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and DeathsTime frame: From first dose to 100 days after last dose (up to 15 months)
- Number of Treated Participant With Laboratory Abnormalities - ThyroidTime frame: From first dose to 100 days after last dose (up to 15 months)
- Number of Treated Participant With Laboratory Abnormalities - LiverTime frame: From first dose to 100 days after last dose (up to 15 months)
- Number of Participants With a Best Overall Response (BOR) - Parts 2 and 3Time frame: From first dose to the last tumor assessment prior to subsequent therapy (up to a maximum of 185 weeks)
- Percentage of Participants With an Objective Response Rate (ORR)- Parts 2 and 3Time frame: From first dose to the last tumor assessment prior to subsequent therapy (up to a maximum of 185 weeks)
- Median Duration of Response (DoR) - Parts 2 and 3Time frame: From first dose to the date of disease progression, death, or until participants withdraw from the study, whichever occurs first (up to a maximum of 185 weeks)
- Progression Free Survival Rate (PFSR) at 24 Weeks - Parts 2 and 3Time frame: At 24 weeks after first dose
- Progression Free Survival Rate (PFSR) at 1 Year - Parts 2 and 3Time frame: At 1 year
- Progression Free Survival Rate (PFSR) at 2 Years - Parts 2 and 3Time frame: At 2 years
Locations
47 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 0028
Tucson, Arizona
Local Institution - 0026
La Jolla, California
Local Institution - 0035
Tampa, Florida
Local Institution - 0005
Atlanta, Georgia
Local Institution - 0048
Atlanta, Georgia
Local Institution - 0027
Chicago, Illinois
Local Institution - 0051
Lutherville, Maryland
Local Institution - 0049
Detroit, Michigan
Local Institution - 0006
St Louis, Missouri
Local Institution - 0033
Hackensack, New Jersey
Local Institution - 0041
New York, New York
Local Institution - 0030
Cleveland, Ohio
Local Institution - 0034
Philadelphia, Pennsylvania
Local Institution - 0057
Pittsburgh, Pennsylvania
Local Institution - 0043
Nashville, Tennessee
Local Institution - 0045
North Sydney, New South Wales, Australia
Local Institution - 0029
Sydney, New South Wales, Australia
Local Institution - 0046
Westmead, New South Wales, Australia
Local Institution - 0044
Brisbane, Queensland, Australia
Local Institution - 0008
Clayton, Victoria, Australia
Local Institution - 0004
Melbourne, Victoria, Australia
Local Institution - 0047
Nedlands, Western Australia, Australia
Local Institution - 0003
Edmonton, Alberta, Canada
Local Institution - 0002
Vancouver, British Columbia, Canada
Local Institution - 0001
Toronto, Ontario, Canada
Local Institution
Greenfield Park, Quebec, Canada
Local Institution - 0036
Montreal, Quebec, Canada
Local Institution - 0059
Helsinki, Finland
Local Institution - 0040
Lille, France
Local Institution - 0024
Lyon, France
Local Institution - 0053
Marseille, France
Local Institution - 0052
Nantes, France
Local Institution - 0025
Paris, France
Local Institution - 0023
Toulouse, France
Local Institution - 0022
Villejuif, France
Local Institution - 0019
Essen, Germany
Local Institution - 0013
Heilbronn, Germany
Local Institution - 0010
Milan, Italy
Local Institution - 0011
Milan, Italy
Local Institution - 0012
Milan, Italy
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.